Copyright
©The Author(s) 2023.
World J Gastrointest Oncol. Nov 15, 2023; 15(11): 1900-1912
Published online Nov 15, 2023. doi: 10.4251/wjgo.v15.i11.1900
Published online Nov 15, 2023. doi: 10.4251/wjgo.v15.i11.1900
Figure 1 Study flow chart.
IrAEs: Immune-related adverse events; NLR: Neutrophil-lymphocyte ratio; PLR: Platelet-lymphocyte ratio.
- Citation: Dharmapuri S, Özbek U, Jethra H, Jun T, Marron TU, Saeed A, Huang YH, Muzaffar M, Pinter M, Balcar L, Fulgenzi C, Amara S, Weinmann A, Personeni N, Scheiner B, Pressiani T, Navaid M, Bengsch B, Paul S, Khan U, Bettinger D, Nishida N, Mohamed YI, Vogel A, Gampa A, Korolewicz J, Cammarota A, Kaseb A, Galle PR, Pillai A, Wang YH, Cortellini A, Kudo M, D’Alessio A, Rimassa L, Pinato DJ, Ang C. Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinoma. World J Gastrointest Oncol 2023; 15(11): 1900-1912
- URL: https://www.wjgnet.com/1948-5204/full/v15/i11/1900.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v15.i11.1900